| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ANIX Stock Overview
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
Anixa Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.82 |
| 52 Week High | US$5.87 |
| 52 Week Low | US$2.30 |
| Beta | 1.53 |
| 1 Month Change | 24.84% |
| 3 Month Change | 19.38% |
| 1 Year Change | -8.61% |
| 3 Year Change | -8.61% |
| 5 Year Change | 479.67% |
| Change since IPO | -95.51% |
Recent News & Updates
Anixa to get additional US patent linked to breast cancer vaccine technology
Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
Shareholder Returns
| ANIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | 4.3% | 1.2% |
| 1Y | -8.6% | -22.1% | -11.6% |
Return vs Industry: ANIX exceeded the US Biotechs industry which returned -25.9% over the past year.
Return vs Market: ANIX exceeded the US Market which returned -13.5% over the past year.
Price Volatility
| ANIX volatility | |
|---|---|
| ANIX Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ANIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ANIX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 5 | Amit Kumar | https://www.anixa.com |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.
Anixa Biosciences, Inc. Fundamentals Summary
| ANIX fundamental statistics | |
|---|---|
| Market Cap | US$116.40m |
| Earnings (TTM) | -US$15.72m |
| Revenue (TTM) | n/a |
9,999x
P/S Ratio-7.4x
P/E RatioIs ANIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANIX income statement (TTM) | |
|---|---|
| Revenue | -US$500.00 |
| Cost of Revenue | US$2.00 |
| Gross Profit | -US$502.00 |
| Other Expenses | US$15.72m |
| Earnings | -US$15.72m |
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 100.40% |
| Net Profit Margin | 3,144,080.00% |
| Debt/Equity Ratio | 0% |
How did ANIX perform over the long term?
See historical performance and comparison